NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcoma

BACKGROUND: T-cell receptor-engineered T-cell therapies have achieved promising response rates against synovial sarcoma in clinical trials, but their applicability is limited owing to the HLA matching requirement. Chimeric antigen receptor (CAR) can redirect primary T cells to tumor-associated antig...

Descripción completa

Detalles Bibliográficos
Autores principales: Murayama, Yudai, Kasahara, Yasushi, Kubo, Nobuhiro, Shin, Chansu, Imamura, Masaru, Oike, Naoki, Ariizumi, Takashi, Saitoh, Akihiko, Baba, Minori, Miyazaki, Tomohiro, Suzuki, Yuko, Ling, Yiwei, Okuda, Shujiro, Mihara, Keichiro, Ogose, Akira, Kawashima, Hiroyuki, Imai, Chihaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420389/
https://www.ncbi.nlm.nih.gov/pubmed/35998437
http://dx.doi.org/10.1016/j.tranon.2022.101521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420389/
https://www.ncbi.nlm.nih.gov/pubmed/35998437
http://dx.doi.org/10.1016/j.tranon.2022.101521

Ejemplares similares